SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community debates its long-term potential, with bullish sentiment fueled by anticipation of a massive token burn event and high holder growth, while skeptics express frustration over recent price stagnation. Investors are actively discussing the token's correlation with the broader meme coin market and monitoring the performance of the BONK ecosystem to gauge the next leg of momentum.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened volatility driven by the emergence of its TurboQuant memory compression technology, which is sparking market concerns over future memory chip demand, alongside ongoing regulatory antitrust scrutiny in Turkey. While investors are actively debating these headwinds, the broader community remains focused on whether these developments represent a temporary headline-driven dip or a shift in the long-term competitive landscape for AI infrastructure.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is under intense pressure as a confluence of weak revenue guidance, rising fuel costs driven by geopolitical instability, and activist-led governance concerns weigh on the stock. While community members are actively debating the potential for a strategic turnaround or buyout, many investors remain wary of ongoing macro headwinds and sector-wide weakness.

APA Corp. explores for oil and natural gas through its subsidiaries. It produces oil and gas with operations in the United States, Egypt and the United Kingdom, and exploration activities offshore in Suriname. The company was founded in 1954 and is headquartered in Houston, TX.

APA Corporation

APA Corporation is trending as investors monitor ongoing geopolitical volatility in the Middle East and its potential impact on global oil supply and energy prices. While market participants debate the stock's valuation and the company's long-term production prospects, community discussion remains focused on energy sector rotation and the firm's overall financial discipline.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently at the center of investor speculation as market participants anticipate high-growth validation in the AI infrastructure supply chain. The community is heavily focused on the company's wafer-level burn-in technology as a critical checkpoint for AI processors and silicon photonics, with significant discourse centered on looming contract announcements and the potential for a massive commercial ramp in the coming quarters.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility as investors weigh the company's aggressive growth and AI integration against concerns over margin pressure and sector-wide regulatory headwinds. While the community remains divided over the long-term sustainability of the gig delivery model, bullish participants are closely watching volume patterns and potential support levels to determine if the stock can sustain its current valuation amid fierce competition.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing significant volatility as market participants debate the stock's valuation amid high-profile AI growth narratives and concerns regarding geopolitical contract risks. The community remains deeply polarized, with active discussions focusing on whether the company represents a high-growth essential technology play or an overvalued asset prone to broader sector pullbacks.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending as investors debate the potential of its high-performance, EVM-compatible blockchain, with many discussing its long-term utility versus short-term market volatility. The community remains polarized, balancing excitement over staking yields and future growth prospects against concerns regarding token supply and price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Key PointsMichael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026...

Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one ha...

Michael Raab Sells 41,666 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the sale, the chief executive officer owned...

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the sale, the chief executive officer...

Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan

Ardelyx (NASDAQ:ARDX) executives outlined commercial momentum for IBSRELA and XPHOZAH, key investment priorities for 2026, and development plans for a chronic idiopathic constipation (CIC) expansion...

Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX

Vanguard Group Inc. grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 14.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving Average - What's Next?

Ardelyx (NASDAQ:ARDX) Stock Price Crosses Below Two Hundred Day Moving Average - Here's What Happened...

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Key PointsMichael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share...

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity...

<ul class="summary-bullets"><li>Director David Mott bought 333,333 shares at a weighted average price of $5.84, lifting his stake to more than 3.3 million shares.</li><li>The insider buy followed a mixed Q4 earnings report in which revenue rose to $125.2 million, beating expectations, while earnings remained flat.</li><li>Ibsrela drove the revenue beat, offsetting softer Xphozah sales, and the company guided for Ibsrela revenue of $410 million to $430 million in 2026.</li></ul>Ardelyx shares jumped more than 5% overnight after a board director made a sizable open-market purchase, adding fuel to growing investor confidence in Ibsrela, the company’s flagship constipation drug.<a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> rose 0.4% on Monday after tumbling 15% on Friday, when the company reported no earnings for the fourth quarter (Q4).<h2 class="st-heading-2">Ardelyx Director Buys 333K Shares In Open Market</h2>According to a new regulatory filing, David Mott, a director at Ardelyx, purchased 333,333 shares of the company’s stock on Friday at a weighted average price of $5.84 per share.The filing shows the purchase was made in multiple open-market transactions, with prices ranging from $5.67 to $6.00. Following the buy, Mott holds over 3.3 million Ardelyx shares.&nbsp;<h2 class="st-heading-2">Ibsrela Drives Q4 Revenue Beat</h2>The insider buy followed Ardelyx’s Q4 earnings report, where revenue rose to $125.2 million, up from $116.1 million a year earlier. The result topped Wall Street expectations of about $119.4 million.The company said the increase was driven largely by higher adoption of Ibsrela, which is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Growth in Ibsrela helped offset softer sales from Xphozah, Ardelyx’s drug for lowering phosphate levels in patients with chronic kidney disease on dialysis.Earnings per share came in at $0.0, compared with $0.02 in the year-ago quarter and slightly below expectations of $0.01.<h2 class="st-heading-2">Strong 2026 Outlook Anchored By Ibsrela</h2>Alongside the results, Ardelyx expects Ibsrela revenue of $410 million to $430 million in 2026, representing growth of at least 50% from 2025 levels. The company cited improvements in prescribing across target healthcare providers, higher patient engagement, and stronger prescription pull-through. For Xphozah, the company forecast 2026 revenue of $110 million to $120 million, up from $103.6 million in 2025.Ardelyx also said it is running additional programs to evaluate Ibsrela in chronic idiopathic constipation and continues to advance its experimental asset RDX10531 across multiple potential indications.<h2 class="st-heading-2">Analysts Reaffirm Bullish Views</h2>On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. Meanwhile, H.C. Wainwright raised its target by 80% to $18 from $10 on Friday, while reiterating a ‘Buy’ rating.H.C. Wainwright said it was encouraged by Ardelyx securing a new U.S. patent extending to November 2042, covering oral formulations of Tenapor, including Ibsrela and Xphozah. Ardelyx has since confirmed that both drugs are now listed in the FDA’s Orange Book, marking a step that strengthens intellectual property protection.CEO Mike Raab previously said the listing was “an important step in extending protections for our portfolio of first-in-class medicines.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for ARDX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rdx_ss_png_9ca239304b.webp" alt="rdx ss.png" width="968" height="140"><figcaption>ARDX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “Maybe retailers will realize now’s the time to buy. Nice buy by mott ”<stembedurl>https://stocktwits.com/mktfixer/message/645684167</stembedurl>Another user said, “Always nice seeing Mr.Mott’s investing in the company. Clearly, he’s in it to win it. He knows what he owns and how the current strategy will be a success. So swell! “<stembedurl>https://stocktwits.com/imlivinit/message/645684336</stembedurl>ARDX stock has declined 1.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Equity

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARDX News

ARDXArdelyx Inc